Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.
The Economist has launched The World Ahead, the annual special year-end issue from The Economist that examines ...
22h
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...
India Today on MSN
Bandi Sanjay's Shocker: AIMIM Backs Gangs Drugging, Abducting Hindu Girls In Hyderabad?
This special report covers Union Minister Bandi Sanjay Kumar's explosive allegations against the AIMIM party in Hyderabad.
The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...
Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking ...
Medicare coverage will cut obesity-drug prices but open the door to millions of new patients.
As can dietary fibers. A systematic review and meta-analysis published in September 2025 found that dietary fiber supplements ...
Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...
El Mundo on MSN
The revolution of the 'Ozempic' drugs and the challenges of a solution for almost everything: "We are facing massive use"
A review by researchers from the Cochrane publication focuses on the new 'superdrugs': questioning the rebound effect, ...
Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback